Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study

BMC Infectious Diseases

Caroline A Sabin⁶  Jens D Lundgren²  Andrew Phillips⁶  Stephane De Wit^1,10  Hansjakob Furrer³  Ole Kirk²  Eric Fontas^1,11  Andrew Grulich⁷  Donald I Abrams¹  Antonella d’Arminio Monforte⁴  Gerd Fätkenheuer⁹  Matthew Law⁷  Fabrice Bonnet⁵  Peter Reiss⁸  Mark Bower^1,12  Signe W Worm² 

[1] Hematology-Oncology, San Francisco General Hospital/University of California, San Francisco, USA;Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark;Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland;Hospital San Paolo, University of Milan, Milan, Italy;ISPED, Universite Victor Segalen, Bordeaux, France;Research Department of Infection and Population Health, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK;Kirby Institute, University of New South Wales, Sydney, Australia;Academic Medical Center, Amsterdam, The Netherlands;University Hospital of Cologne, Cologne, Germany;Department of Infectious Diseases, CHU Saint-Pierre Hospital, Bruxelles, Belgium;CHU Nice Hopital de l’Archet, Nice, France;Chelsea and Westminster Hospital, London, UK

关键词: Prognosis;    Trends;    Incidence;    Non-AIDS defining cancers;    HIV;   

Others  :  1145702
DOI  :  10.1186/1471-2334-13-471

 received in 2013-04-30, accepted in 2013-10-04,  发布年份 2013

【 摘 要 】

Background

Non-AIDS defining cancers (NADC) are an important cause of morbidity and mortality in HIV-positive individuals. Using data from a large international cohort of HIV-positive individuals, we described the incidence of NADC from 2004–2010, and described subsequent mortality and predictors of these.

Methods

Individuals were followed from 1st January 2004/enrolment in study, until the earliest of a new NADC, 1st February 2010, death or six months after the patient’s last visit. Incidence rates were estimated for each year of follow-up, overall and stratified by gender, age and mode of HIV acquisition. Cumulative risk of mortality following NADC diagnosis was summarised using Kaplan-Meier methods, with follow-up for these analyses from the date of NADC diagnosis until the patient’s death, 1st February 2010 or 6 months after the patient’s last visit. Factors associated with mortality following NADC diagnosis were identified using multivariable Cox proportional hazards regression.

Results

Over 176,775 person-years (PY), 880 (2.1%) patients developed a new NADC (incidence: 4.98/1000PY [95% confidence interval 4.65, 5.31]). Over a third of these patients (327, 37.2%) had died by 1st February 2010. Time trends for lung cancer, anal cancer and Hodgkin’s lymphoma were broadly consistent. Kaplan-Meier cumulative mortality estimates at 1, 3 and 5 years after NADC diagnosis were 28.2% [95% CI 25.1-31.2], 42.0% [38.2-45.8] and 47.3% [42.4-52.2], respectively. Significant predictors of poorer survival after diagnosis of NADC were lung cancer (compared to other cancer types), male gender, non-white ethnicity, and smoking status. Later year of diagnosis and higher CD4 count at NADC diagnosis were associated with improved survival. The incidence of NADC remained stable over the period 2004–2010 in this large observational cohort.

Conclusions

The prognosis after diagnosis of NADC, in particular lung cancer and disseminated cancer, is poor but has improved somewhat over time. Modifiable risk factors, such as smoking and low CD4 counts, were associated with mortality following a diagnosis of NADC.

【 授权许可】

   
2013 Worm et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mocroft A, Ledergerber B, Katlama C, et al.: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29.
• [2]Engels EA, Pfeiffer RM, Goedert JJ, et al.: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006, 20:1645-1654.
• [3]Simard EP, Pfeiffer RM, Engels EA: Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010, 170:1337-1345.
• [4]Shiels MS, Pfeiffer RM, Gail MH, et al.: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011, 103:753-762.
• [5]Patel P, Hanson DL, Sullivan PS, et al.: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008, 148:728-736.
• [6]Powles T, Robinson D, Stebbing J, et al.: Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009, 27:884-890.
• [7]Franceschi S, Lise M, Clifford GM, et al.: Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV cohort study. Brit J Cancer 2010, 103:416-422.
• [8]Long JL, Engels EA, Moore RD, Gebo KA: Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008, 22:489-496.
• [9]Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S: The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007, 165:1143-1153.
• [10]Silverberg MJ, Lau B, Justice AC, et al.: Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012, 54:1026-1034.
• [11]Piketty C, Selinger-Leneman H, Bouvier AM, et al.: Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French Hospital Database on HIV. J Clin Oncol 2012, 30:4360-4366.
• [12]Bonnet F, Burty C, Lewden C, et al.: Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009, 48:633-639.
• [13]Simard EP, Engels EA: Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 2010, 51:957-962.
• [14]Hasse B, Ledergerber B, Furrer H, et al.: Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011, 53:1130-1139.
• [15]Lowsky R, Lipton J, Fyles G, et al.: Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994, 12:2187-2192.
• [16]Curtis RE, Rowlings PA, Deeg HJ, et al.: Solid cancers after bone marrow transplantation. N Engl J Med 1997, 336:897-904.
• [17]Tirelli U, Errante D, Dolcetti R, et al.: Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian cooperative group on AIDS and tumors. J Clin Oncol 1995, 13:1758-1767.
• [18]Biggar RJ, Engels EA, Ly S, et al.: Survival after cancer diagnosis in persons with AIDS. J Acquir Imm Defic Syndr 2005, 39:293-299.
• [19]Achenbach CJ, Cole SR, Kitahata MM, et al.: Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011, 25:691-700.
• [20]Clifford GM, Polesel J, Rickenbach M, et al.: Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005, 97:425-432.
• [21]Friis-Møller N, Sabin CA, Weber R, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
• [22]Kowalska JD, Friis-Moller N, Kirk O, et al.: The coding causes of death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011, 22:516-523.
• [23]Reekie J, Kosa C, Engsig F, et al.: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010, 116:5306-5315.
• [24]Herida M, Mary-Krause M, Kaphan R, et al.: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003, 21:3447-3453.
• [25]Spagnuolo V, Galli L, Salpietro S, et al.: Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer 2012, 130:2990-2996.
• [26]Machalek DA, Poynten M, Jin F, et al.: Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012, 13:487-500.
• [27]Jin F, Stein AN, Conway EL, et al.: Trends in anal cancer in Australia 1982–2005. Vaccine 2011, 29:2322-2327.
• [28]Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002, 16:1155-1161.
• [29]Shiels MS, Cole SR, Mehta SH, Kirk GD: Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Aquir Immune Defic Syndr 2010, 55:510-515.
• [30]Hoffmann C, Chow KU, Wolf E, et al.: Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol 2004, 125:455-462.
• [31]Xicoy B, Ribera JM, Miralles P, et al.: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica 2007, 92:191-198.
• [32]Bower M, Powles T, Newsom-Davis T, et al.: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004, 37:1563-1565.
• [33]Munoz-Bongrand N, Poghosyan T, Zohar S, et al.: Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. Dis Colon Rectum 2011, 54:729-735.